TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
10x Genomics Sweden AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
13,178
|
24,112
|
23,030 |
| Financial expenses |
7
|
28
|
1 |
| Earnings before taxes |
5,580
|
13,864
|
12,206 |
| EBITDA |
5,680
|
14,725
|
13,062 |
| Total assets |
9,262
|
33,366
|
23,400 |
| Current assets |
9,262
|
31,650
|
20,864 |
| Current liabilities |
2,192
|
3,177
|
5,051 |
| Equity capital |
7,070
|
30,190
|
18,349 |
| - share capital |
4
|
5
|
4 |
| Employees (average) |
19
|
39
|
45 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
76.3%
|
90.5%
|
78.4% |
| Turnover per employee |
694
|
618
|
512 |
| Profit as a percentage of turnover |
42.3%
|
57.5%
|
53.0% |
| Return on assets (ROA) |
60.3%
|
41.6%
|
52.2% |
| Current ratio |
422.5%
|
996.2%
|
413.1% |
| Return on equity (ROE) |
78.9%
|
45.9%
|
66.5% |
| Change turnover |
-10,114
|
1,015
|
8,726 |
| Change turnover % |
-43%
|
4%
|
61% |
| Chg. No. of employees |
-20
|
-6
|
7 |
| Chg. No. of employees % |
-51%
|
-13%
|
18% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.